Skip to main content
Top
Published in: Diabetologia 1/2013

01-01-2013 | Article

Production and function of IL-12 in islets and beta cells

Authors: D. A. Taylor-Fishwick, J. R. Weaver, W. Grzesik, S. Chakrabarti, S. Green-Mitchell, Y. Imai, N. Kuhn, J. L. Nadler

Published in: Diabetologia | Issue 1/2013

Login to get access

Abstract

Aims/hypothesis

IL-12 is an important cytokine in early inflammatory responses and is implicated in the immune-mediated pathogenesis of pancreatic islets in diabetes. However, little is known about the direct effects of IL-12 on islets and beta cells.

Methods

In this study, beta cell function, gene expression and protein production were assessed in primary human donor islets and murine beta cell lines in response to stimulation with IL-12 or a pro-inflammatory cytokine cocktail (TNF-α, IL-1β and IFN-γ).

Results

The pro-inflammatory cytokine cocktail induced islet dysfunction and potently increased the expression and production of IL-12 ligand and IL-12 receptor in human islets. In human islets, the receptor for IL-12 co-localised to the cell surface of insulin-producing cells. Both IL-12 ligand and IL-12 receptor are expressed in the homogeneous beta cell line INS-1. IL-12 induced changes in gene expression, including a dose-dependent upregulation of IFNγ (also known as IFNG), in INS-1 cells. A neutralising antibody to IL-12 directly inhibited IFNγ gene expression in human donor islets induced by either IL-12 or pro-inflammatory cytokine stimulation. Functionally, IL-12 impaired glucose-stimulated insulin secretion (GSIS) in INS-1 cells and human donor islets. A neutralising antibody to IL-12 reversed the beta cell dysfunction (uncoupling of GSIS or induction of caspase-3 activity) induced by pro-inflammatory cytokines.

Conclusions/interpretation

These data identify beta cells as a local source of IL-12 ligand and suggest a direct role of IL-12 in mediating beta cell pathology.
Appendix
Available only for authorised users
Literature
1.
go back to reference Katz JD, Benoist C, Mathis D (1995) T helper cell subsets in insulin-dependent diabetes. Science 268:1185–1188PubMedCrossRef Katz JD, Benoist C, Mathis D (1995) T helper cell subsets in insulin-dependent diabetes. Science 268:1185–1188PubMedCrossRef
3.
go back to reference Serreze DV, Chapman HD, Varnum DS, Gerling I, Leiter EH, Shultz LD (1997) Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. J Immunol 158:3978–3986PubMed Serreze DV, Chapman HD, Varnum DS, Gerling I, Leiter EH, Shultz LD (1997) Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. J Immunol 158:3978–3986PubMed
4.
go back to reference Trembleau S, Germann T, Gately MK, Adorini L (1995) The role of IL-12 in the induction of organ specific autoimmune diseases. Immunol Today 16:383–386PubMedCrossRef Trembleau S, Germann T, Gately MK, Adorini L (1995) The role of IL-12 in the induction of organ specific autoimmune diseases. Immunol Today 16:383–386PubMedCrossRef
5.
go back to reference Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L (1995) Interleukin 12 administration induces T helper type I cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 181:817–821PubMedCrossRef Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L (1995) Interleukin 12 administration induces T helper type I cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 181:817–821PubMedCrossRef
6.
go back to reference Athie M, Flotow H, Hilyard KL, Cantrell DA (2000) IL-12 selectively regulates STAT4 via phosphatidylinositol 3-kinase and Ras-independent signal transduction pathways. Eur J Immunol 30:1425–1434CrossRef Athie M, Flotow H, Hilyard KL, Cantrell DA (2000) IL-12 selectively regulates STAT4 via phosphatidylinositol 3-kinase and Ras-independent signal transduction pathways. Eur J Immunol 30:1425–1434CrossRef
7.
go back to reference Visconti R, Gadina M, Chiariello M et al (2000) Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity. Blood 96:1844–1852PubMed Visconti R, Gadina M, Chiariello M et al (2000) Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity. Blood 96:1844–1852PubMed
8.
go back to reference Kaplan MH, Sun YI, Hoey T, Grusby MJ (1996) Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382:174–177PubMedCrossRef Kaplan MH, Sun YI, Hoey T, Grusby MJ (1996) Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382:174–177PubMedCrossRef
9.
go back to reference Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ (2004) Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 202:139–156PubMedCrossRef Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ (2004) Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 202:139–156PubMedCrossRef
10.
go back to reference Watford WT, Moriguchi M, Morinobu A, O'Shea JJ (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14:361–368PubMedCrossRef Watford WT, Moriguchi M, Morinobu A, O'Shea JJ (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14:361–368PubMedCrossRef
11.
go back to reference Morinobu A, Gadina M, Strober W et al (2002) STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci USA 99:12281–12286PubMedCrossRef Morinobu A, Gadina M, Strober W et al (2002) STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci USA 99:12281–12286PubMedCrossRef
12.
go back to reference Nguyen T, Wang R, Russell JH (2000) IL-12 enhances IL-2 function by inducing CD25 expression through a p38 mitogen-activated protein kinase pathway. Eur J Immunol 30:1445–1452PubMedCrossRef Nguyen T, Wang R, Russell JH (2000) IL-12 enhances IL-2 function by inducing CD25 expression through a p38 mitogen-activated protein kinase pathway. Eur J Immunol 30:1445–1452PubMedCrossRef
13.
go back to reference Vandenbroeck K, Alloza I, Gadina M, Matthys P (2004) Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol 56:145–160PubMedCrossRef Vandenbroeck K, Alloza I, Gadina M, Matthys P (2004) Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol 56:145–160PubMedCrossRef
14.
go back to reference Morahan G, Huang D, Ymer SI et al (2001) Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nat Genet 27:218–221PubMedCrossRef Morahan G, Huang D, Ymer SI et al (2001) Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nat Genet 27:218–221PubMedCrossRef
15.
go back to reference Altinova AE, Engin D, Akbay E et al (2010) Association of polymorphisms in the IL-18 and IL-12 genes with susceptibility to Type 1 diabetes in Turkish patients. J Endocrinol Invest 33:451–454PubMed Altinova AE, Engin D, Akbay E et al (2010) Association of polymorphisms in the IL-18 and IL-12 genes with susceptibility to Type 1 diabetes in Turkish patients. J Endocrinol Invest 33:451–454PubMed
16.
go back to reference Morahan G, McKinnon E, Berry J et al (2009) Evaluation of IL12B as a candidate type I diabetes susceptibility gene using data from the Type I Diabetes Genetics Consortium. Genes Immun 10(Suppl 1):S64–S68PubMedCrossRef Morahan G, McKinnon E, Berry J et al (2009) Evaluation of IL12B as a candidate type I diabetes susceptibility gene using data from the Type I Diabetes Genetics Consortium. Genes Immun 10(Suppl 1):S64–S68PubMedCrossRef
17.
go back to reference Morgan D, Oliveira-Emilio HR, Keane D et al (2007) Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia 50:359–369PubMedCrossRef Morgan D, Oliveira-Emilio HR, Keane D et al (2007) Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia 50:359–369PubMedCrossRef
18.
go back to reference Pi J, Bai Y, Zhang Q et al (2007) Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes 56:1783–1791PubMedCrossRef Pi J, Bai Y, Zhang Q et al (2007) Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes 56:1783–1791PubMedCrossRef
19.
go back to reference Modak MA, Parab PB, Ghaskadbi SS (2009) Pancreatic islets are very poor in rectifying oxidative DNA damage. Pancreas 38:23–29PubMedCrossRef Modak MA, Parab PB, Ghaskadbi SS (2009) Pancreatic islets are very poor in rectifying oxidative DNA damage. Pancreas 38:23–29PubMedCrossRef
20.
go back to reference Mandrup-Poulsen T (2003) Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 66:1433–1440PubMedCrossRef Mandrup-Poulsen T (2003) Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 66:1433–1440PubMedCrossRef
21.
go back to reference Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M (2008) Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide-1. J Mol Endocrinol 41:35–44PubMedCrossRef Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M (2008) Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide-1. J Mol Endocrinol 41:35–44PubMedCrossRef
22.
go back to reference Lund T, Fosby B, Korsgren O, Scholz H, Foss A (2008) Glucocorticoids reduce pro-inflammatory cytokines and tissue factor in vitro and improve function of transplanted human islets in vivo. Transpl Int 21:669–678PubMedCrossRef Lund T, Fosby B, Korsgren O, Scholz H, Foss A (2008) Glucocorticoids reduce pro-inflammatory cytokines and tissue factor in vitro and improve function of transplanted human islets in vivo. Transpl Int 21:669–678PubMedCrossRef
23.
go back to reference Boden G (2011) Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 18:139–143PubMedCrossRef Boden G (2011) Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 18:139–143PubMedCrossRef
24.
go back to reference Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, Nadler JL (2010) 12-Lipoxygenase products reduce insulin secretion and β cell viability in human islets. J Clin Endocrinol Metab 95:887–893PubMedCrossRef Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, Nadler JL (2010) 12-Lipoxygenase products reduce insulin secretion and β cell viability in human islets. J Clin Endocrinol Metab 95:887–893PubMedCrossRef
25.
go back to reference Yang Z, Chen M, Ellett JD et al (2004) Autoimmune diabetes is blocked in Stat4-deficient mice. J Autoimmun 22:191–200PubMedCrossRef Yang Z, Chen M, Ellett JD et al (2004) Autoimmune diabetes is blocked in Stat4-deficient mice. J Autoimmun 22:191–200PubMedCrossRef
26.
go back to reference Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, Nadler JL (2003) The novel anti-inflammtory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice. Pancreas 26:e99–e104PubMedCrossRef Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, Nadler JL (2003) The novel anti-inflammtory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice. Pancreas 26:e99–e104PubMedCrossRef
27.
go back to reference Jorns A, Gunther A, Hedrich HJ, Wedekind D, Tiedge M, Lenzen S (2005) Immune cell infiltration, cytokine expression, and beta-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat. Diabetes 54:2041–2052PubMedCrossRef Jorns A, Gunther A, Hedrich HJ, Wedekind D, Tiedge M, Lenzen S (2005) Immune cell infiltration, cytokine expression, and beta-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat. Diabetes 54:2041–2052PubMedCrossRef
28.
go back to reference Catalan V, Gomez-Ambrosi J, Ramirez B et al (2007) Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg 17:1464–1474PubMedCrossRef Catalan V, Gomez-Ambrosi J, Ramirez B et al (2007) Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg 17:1464–1474PubMedCrossRef
29.
go back to reference Igoillo-Esteve M, Marselli L, Cunha DA et al (2010) Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia 53:1395–1405PubMedCrossRef Igoillo-Esteve M, Marselli L, Cunha DA et al (2010) Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia 53:1395–1405PubMedCrossRef
30.
go back to reference Steinberg GR (2007) Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle 6:888–894PubMedCrossRef Steinberg GR (2007) Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle 6:888–894PubMedCrossRef
31.
go back to reference Michalska M, Wolf G, Walther R, Newsholme P (2010) Effects of pharmacological inhibition of NADPH oxidase or iNOS on pro-inflammatory cytokine, palmitic acid or H2O2-induced mouse islet or clonal pancreatic beta cell dysfunction. Biosci Rep 30:445–453PubMedCrossRef Michalska M, Wolf G, Walther R, Newsholme P (2010) Effects of pharmacological inhibition of NADPH oxidase or iNOS on pro-inflammatory cytokine, palmitic acid or H2O2-induced mouse islet or clonal pancreatic beta cell dysfunction. Biosci Rep 30:445–453PubMedCrossRef
32.
go back to reference Yang ZD, Chen M, Wu R, McDuffie M, Nadler JL (2002) The anti-inflammatory compound lisofylline prevents Type 1 diabetes in non-obese diabetic mice. Diabetologia 45:1307–1314PubMedCrossRef Yang ZD, Chen M, Wu R, McDuffie M, Nadler JL (2002) The anti-inflammatory compound lisofylline prevents Type 1 diabetes in non-obese diabetic mice. Diabetologia 45:1307–1314PubMedCrossRef
33.
go back to reference Lenzen S, Drinkgern J, Tiedge M (1996) Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 20:463–466PubMedCrossRef Lenzen S, Drinkgern J, Tiedge M (1996) Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 20:463–466PubMedCrossRef
34.
35.
go back to reference Azevedo-Martins AK, Lortz S, Lenzen S, Curi R, Eizirik DL, Tiedge M (2003) Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-kappaB activation in insulin-producing cells. Diabetes 52:93–101PubMedCrossRef Azevedo-Martins AK, Lortz S, Lenzen S, Curi R, Eizirik DL, Tiedge M (2003) Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-kappaB activation in insulin-producing cells. Diabetes 52:93–101PubMedCrossRef
36.
go back to reference Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL (2001) Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia 44:325–332PubMedCrossRef Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL (2001) Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia 44:325–332PubMedCrossRef
37.
go back to reference Marzorati S, Antonioli B, Nano R et al (2006) Culture medium modulates proinflammatory conditions of human pancreatic islets before transplantation. Am J Transplant 6:2791–2795PubMedCrossRef Marzorati S, Antonioli B, Nano R et al (2006) Culture medium modulates proinflammatory conditions of human pancreatic islets before transplantation. Am J Transplant 6:2791–2795PubMedCrossRef
38.
go back to reference Rabinovitch A, Sumoski W, Rajotte RV, Warnock GL (1990) Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J Clin Endocrinol Metab 71:152–156PubMedCrossRef Rabinovitch A, Sumoski W, Rajotte RV, Warnock GL (1990) Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J Clin Endocrinol Metab 71:152–156PubMedCrossRef
39.
go back to reference Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526PubMedCrossRef Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526PubMedCrossRef
40.
go back to reference Mandrup-Poulsen T, Pickersgill L, Donath MY (2010) Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 6:158–166PubMedCrossRef Mandrup-Poulsen T, Pickersgill L, Donath MY (2010) Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 6:158–166PubMedCrossRef
41.
go back to reference Oppmann B, Lesley R, Blom B et al (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715–725PubMedCrossRef Oppmann B, Lesley R, Blom B et al (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715–725PubMedCrossRef
42.
go back to reference Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665–1674PubMedCrossRef Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665–1674PubMedCrossRef
43.
go back to reference Rabinovitch A, Suarez-Pinzon WL, Sorensen O (1996) Interleukin 12 mRNA expression in islets correlates with beta-cell destruction in NOD mice. J Autoimmun 9:645–651PubMedCrossRef Rabinovitch A, Suarez-Pinzon WL, Sorensen O (1996) Interleukin 12 mRNA expression in islets correlates with beta-cell destruction in NOD mice. J Autoimmun 9:645–651PubMedCrossRef
44.
go back to reference Zipris D, Greiner DL, Malkani S, Whalen B, Mordes JP, Rossini AA (1996) Cytokine gene expression in islets and thyroids of BB rats. IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic BB rats. J Immunol 156:1315–1321PubMed Zipris D, Greiner DL, Malkani S, Whalen B, Mordes JP, Rossini AA (1996) Cytokine gene expression in islets and thyroids of BB rats. IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic BB rats. J Immunol 156:1315–1321PubMed
45.
go back to reference O'Hara RM Jr, Henderson SL, Nagelin A (1996) Prevention of a Th1 disease by a Th1 cytokine: IL-12 and diabetes in NOD mice. Ann NY Acad Sci 795:241–249PubMedCrossRef O'Hara RM Jr, Henderson SL, Nagelin A (1996) Prevention of a Th1 disease by a Th1 cytokine: IL-12 and diabetes in NOD mice. Ann NY Acad Sci 795:241–249PubMedCrossRef
46.
go back to reference Rothe H, O'Hara RM Jr, Martin S, Kolb H (1997) Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)2. Diabetologia 40:641–646PubMedCrossRef Rothe H, O'Hara RM Jr, Martin S, Kolb H (1997) Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)2. Diabetologia 40:641–646PubMedCrossRef
47.
go back to reference Trembleau S, Penna G, Gregori S, Gately MK, Adorini L (1997) Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 27:2330–2339PubMedCrossRef Trembleau S, Penna G, Gregori S, Gately MK, Adorini L (1997) Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 27:2330–2339PubMedCrossRef
48.
go back to reference Holz A, Brett K, Oldstone MB (2001) Constitutive beta cell expression of IL-12 does not perturb self-tolerance but intensifies established autoimmune diabetes. J Clin Invest 108:1749–1758PubMed Holz A, Brett K, Oldstone MB (2001) Constitutive beta cell expression of IL-12 does not perturb self-tolerance but intensifies established autoimmune diabetes. J Clin Invest 108:1749–1758PubMed
49.
go back to reference Mishra M, Kumar H, Bajpai S, Singh RK, Tripathi K (2011) Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed T2DM. Diabetes Res Clin Pract 94:255–261PubMedCrossRef Mishra M, Kumar H, Bajpai S, Singh RK, Tripathi K (2011) Level of serum IL-12 and its correlation with endothelial dysfunction, insulin resistance, proinflammatory cytokines and lipid profile in newly diagnosed T2DM. Diabetes Res Clin Pract 94:255–261PubMedCrossRef
50.
go back to reference Boyton RJ, Davies S, Marden C et al (2005) Stat4-null non-obese diabetic mice: protection from diabetes and experimental allergic encephalomyelitis, but with concomitant epitope spread. Int Immunol 17:1157–1165PubMedCrossRef Boyton RJ, Davies S, Marden C et al (2005) Stat4-null non-obese diabetic mice: protection from diabetes and experimental allergic encephalomyelitis, but with concomitant epitope spread. Int Immunol 17:1157–1165PubMedCrossRef
Metadata
Title
Production and function of IL-12 in islets and beta cells
Authors
D. A. Taylor-Fishwick
J. R. Weaver
W. Grzesik
S. Chakrabarti
S. Green-Mitchell
Y. Imai
N. Kuhn
J. L. Nadler
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2732-9

Other articles of this Issue 1/2013

Diabetologia 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.